BPC 157

BPC-157 ("Body Protection Compound 157") is a synthetic pentadecapeptide, a chain of 15 amino acids with the sequence GEPPPGKPADDAGLV. It corresponds to a partial sequence of a protein found in human gastric juice and was first described by researchers in Zagreb in the early 1990s. It is supplied as a lyophilized powder for laboratory research.

No. BPC-157 is not approved by the FDA for any use. In 2023 the FDA listed it among bulk drug substances that raise significant safety concerns for use in compounding, and the World Anti-Doping Agency has named it on its Prohibited List since 2022. It is sold here strictly as a research compound.

They are unrelated molecules. BPC-157 is a synthetic 15-amino-acid peptide (GEPPPGKPADDAGLV) based on a partial sequence of a protein found in gastric juice. TB-500 is the name used for synthetic peptides derived from thymosin β4, a 43-amino-acid protein that binds actin inside cells; depending on the supplier it denotes the full-length sequence or a fragment around its actin-binding region. They differ in length, sequence, origin and the cellular pathways studied, and are often supplied together as a co-lyophilized blend for convenience in research.

Much less time than as a dry powder. Most reconstituted peptides are kept refrigerated at 2–8 °C and used within a few weeks; the exact window depends on the peptide's sequence, the diluent, and how carefully the vial is handled. Avoid repeated freeze-thaw cycles and light exposure. Lyophilized powder kept cold and dry stays stable far longer.

These belong to unrelated research areas. BPC-157 (a 15-amino-acid gastric-protein-derived peptide) and TB-500 (derived from the actin-binding protein thymosin β4) are studied in tissue-repair models. CJC-1295, sermorelin and tesamorelin are GHRH analogues acting on the GHRH receptor in the growth hormone axis. They share no sequence, receptor or pathway.

They are unrelated peptides. MGF is a 24-amino-acid peptide from the E-domain of an IGF-1 splice variant, studied in muscle-cell models. BPC-157 is a 15-amino-acid synthetic peptide based on a partial sequence of a gastric-juice protein, studied in tissue-repair models. They differ in origin, sequence and the pathways examined.

Published research on BPC-157 has been mainly preclinical, in cell and rodent models, much of it from the University of Zagreb group that first described the peptide. These studies examine gastrointestinal, tendon, ligament and blood-vessel tissue models, and signaling pathways such as nitric oxide, VEGF receptor 2 and focal adhesion kinase. Published human data are very limited, and it has not completed clinical development for any use. Findings in cells or animals do not establish effects in people.

BPC-157 is a chain of 15 amino acids (a pentadecapeptide): Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with a molecular weight of about 1419.5 Da. It is made by solid-phase chemical synthesis, which builds the chain one amino acid at a time, and is supplied as a lyophilized powder, usually as an acetate salt. The salt form and purity of each lot are shown on its Certificate of Analysis.

No. BPC-157 is not a GLP-1 analogue and is not described in the published literature as a GLP-1 receptor agonist. GLP-1 analogues such as semaglutide are built on the sequence of glucagon-like peptide-1, a gut hormone of about 30 amino acids. BPC-157's 15-amino-acid sequence comes from a protein found in gastric juice and shares no sequence with GLP-1.

In the United States, BPC-157 is not an approved drug, so it cannot lawfully be marketed or sold as a medicine for human or veterinary use. It is sold as a research chemical for laboratory use only, which is how we supply it. It is also on the World Anti-Doping Agency's Prohibited List. Rules differ from country to country, so researchers outside the U.S. should check local regulations.

Yes. BPC-157 has been named on the World Anti-Doping Agency Prohibited List since 2022, in class S0 (non-approved substances). S0 covers any pharmacological substance that no government regulatory authority has approved for human therapeutic use, and it is prohibited at all times, in and out of competition. Sports organizations that follow the WADA Code apply the same list; others, such as collegiate athletic associations, publish their own banned-substance lists.

For storage, yes. Keep lyophilized BPC-157 sealed, dry and away from light, refrigerated at 2–8 °C, or frozen at −20 °C for long-term storage. The dry powder tolerates room temperature for short periods, such as during shipping. Once reconstituted, keep the solution refrigerated, avoid repeated freeze-thaw cycles, and label the vial with the date and concentration.

BPC-157 dissolves readily in water-based diluents such as bacteriostatic water or sterile water. Let the sealed vial reach room temperature, add the diluent slowly down the inside wall of the vial rather than onto the powder, and swirl gently until the solution is clear; do not shake. The concentration is the labeled mass divided by the volume of diluent added. Label the vial with the date and concentration and keep it refrigerated.

They are unrelated peptides that are often discussed in the same research areas. BPC-157 is a synthetic 15-amino-acid peptide based on a protein found in gastric juice. KPV is the tripeptide Lys-Pro-Val, the C-terminal end of α-melanocyte-stimulating hormone (α-MSH). BPC-157 research has focused on nitric oxide and growth-factor signaling in tissue models, while KPV has been studied in cell and rodent models of inflammation. Both are components of the four-peptide blend we sell.

BPC-157 is a synthetic 15-amino-acid peptide with no metal attached. GHK-Cu is a copper(II) complex of the tripeptide Gly-His-Lys, which occurs naturally in human plasma. BPC-157 research centers on nitric oxide and growth-factor signaling, while GHK-Cu research centers on copper transport, gene expression and extracellular-matrix components such as collagen in cell culture, and it is widely used in cosmetic science. Both appear, with TB-500, in the multi-peptide blends we sell.

They are unrelated peptides. Ara-290 is an 11-amino-acid peptide derived from erythropoietin and designed for the proposed innate repair receptor; it has been through phase 2 clinical trials. BPC-157 is a 15-amino-acid peptide based on a protein found in gastric juice, studied mainly in rodent models of nitric oxide and growth-factor signaling. They share no sequence or receptor.

BPC 157: molecular formula C62H98N16O22; molecular weight 1419.5 g/mol; CAS number 137525-51-0. Sequence: GEPPPGKPADDAGLV. Match these identifiers against the Certificate of Analysis for the lot.

Yes. Each lot has its own Certificate of Analysis, linked on this page for the current lot of each size: 10mg (99.66% HPLC purity). Past certificates are archived in the COA library; contact us with the lot number on the vial label if a certificate is missing.

99.66% (HPLC, current lot). Purity is measured by high-performance liquid chromatography (HPLC) and reported on the lot's Certificate of Analysis.

BPC 157 is supplied as lyophilized powder in a sealed vial: 10mg. In stock and dispatched in 1–2 business days. Quantity pricing applies automatically at 5+ and 10+ vials of the same size.

Store sealed at −20 °C, dry and protected from light.